170 related articles for article (PubMed ID: 24666203)
1. Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.
Phillips DP; Gao W; Yang Y; Zhang G; Lerario IK; Lau TL; Jiang J; Wang X; Nguyen DG; Bhat BG; Trotter C; Sullivan H; Welzel G; Landry J; Chen Y; Joseph SB; Li C; Gordon WP; Richmond W; Johnson K; Bretz A; Bursulaya B; Pan S; McNamara P; Seidel HM
J Med Chem; 2014 Apr; 57(8):3263-82. PubMed ID: 24666203
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes.
Agarwal S; Sasane S; Kumar J; Deshmukh P; Bhayani H; Giri P; Giri S; Soman S; Kulkarni N; Jain M
Bioorg Med Chem Lett; 2018 Jun; 28(10):1849-1852. PubMed ID: 29655980
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists.
Dehmlow H; Alvarez Sánchez R; Bachmann S; Bissantz C; Bliss F; Conde-Knape K; Graf M; Martin RE; Obst Sander U; Raab S; Richter HG; Sewing S; Sprecher U; Ullmer C; Mattei P
Bioorg Med Chem Lett; 2013 Aug; 23(16):4627-32. PubMed ID: 23831134
[TBL] [Abstract][Full Text] [Related]
6. OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.
Ma SY; Ning MM; Zou QA; Feng Y; Ye YL; Shen JH; Leng Y
Acta Pharmacol Sin; 2016 Sep; 37(10):1359-1369. PubMed ID: 27264313
[TBL] [Abstract][Full Text] [Related]
7. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
8. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists.
Sakairi M; Kogami M; Torii M; Kuno Y; Ohsawa Y; Makino M; Kataoka D; Okamoto R; Miyazawa T; Inoue M; Takahashi N; Harada S; Watanabe N
Arzneimittelforschung; 2012 Nov; 62(11):537-44. PubMed ID: 22972470
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
[TBL] [Abstract][Full Text] [Related]
11. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
[TBL] [Abstract][Full Text] [Related]
13. Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice.
Briere DA; Ruan X; Cheng CC; Siesky AM; Fitch TE; Dominguez C; Sanfeliciano SG; Montero C; Suen CS; Xu Y; Coskun T; Michael MD
PLoS One; 2015; 10(8):e0136873. PubMed ID: 26312995
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists.
Duan H; Ning M; Chen X; Zou Q; Zhang L; Feng Y; Zhang L; Leng Y; Shen J
J Med Chem; 2012 Dec; 55(23):10475-89. PubMed ID: 23148522
[TBL] [Abstract][Full Text] [Related]
15. G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) agonists reduce the production of proinflammatory cytokines and stabilize the alternative macrophage phenotype.
Högenauer K; Arista L; Schmiedeberg N; Werner G; Jaksche H; Bouhelal R; Nguyen DG; Bhat BG; Raad L; Rauld C; Carballido JM
J Med Chem; 2014 Dec; 57(24):10343-54. PubMed ID: 25411721
[TBL] [Abstract][Full Text] [Related]
16. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
17. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
Mikami S; Kitamura S; Negoro N; Sasaki S; Suzuki M; Tsujihata Y; Miyazaki T; Ito R; Suzuki N; Miyazaki J; Santou T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
J Med Chem; 2012 Apr; 55(8):3756-76. PubMed ID: 22428944
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.
Herbert MR; Siegel DL; Staszewski L; Cayanan C; Banerjee U; Dhamija S; Anderson J; Fan A; Wang L; Rix P; Shiau AK; Rao TS; Noble SA; Heyman RA; Bischoff E; Guha M; Kabakibi A; Pinkerton AB
Bioorg Med Chem Lett; 2010 Oct; 20(19):5718-21. PubMed ID: 20801037
[TBL] [Abstract][Full Text] [Related]
19. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists.
Miyata S; Kawashima Y; Sakai M; Matsubayashi M; Motoki K; Miyajima Y; Watanabe Y; Chikamatsu N; Taniguchi T; Tokuyama R
Sci Rep; 2021 Apr; 11(1):9196. PubMed ID: 33911126
[TBL] [Abstract][Full Text] [Related]
20. Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).
Chen T; Reich NW; Bell N; Finn PD; Rodriguez D; Kohler J; Kozuka K; He L; Spencer AG; Charmot D; Navre M; Carreras CW; Koo-McCoy S; Tabora J; Caldwell JS; Jacobs JW; Lewis JG
J Med Chem; 2018 Sep; 61(17):7589-7613. PubMed ID: 30141927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
